Charles Kidd, MD
Urology · Milwaukee, WINPI 1508834193
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,445 of the $5,318 with a category attached, or 83.6%. It is spread thinly across 33 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,033 and has fallen 59.6% since, to $821 in 2025.
Across 183 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Astellas Pharma US Inc$973
- Pfizer$407
- Medtronic$314
- Procept Biorobotics Corporation$301
- Johnson & Johnson$246
- plus $2K from 27 others
What the payments were for
- Travel & lodging$56411%
- Food & beverage$4,44584%
- Education$3096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 13 | $1,040 |
| Astellas Pharma US Inc | 41 | $973 |
| Pfizer | 23 | $407 |
| Medtronic(2 entities) | 10 | $314 |
| Procept Biorobotics Corporation | 3 | $301 |
| Johnson & Johnson(2 entities) | 8 | $246 |
| AstraZeneca | 7 | $211 |
| AbbVie | 11 | $196 |
| Calyxo, Inc. | 1 | $179 |
| Endo Pharmaceuticals Inc. | 9 | $178 |
| Rochester Medical Corporation | 4 | $175 |
| Teleflex LLC | 3 | $117 |
| Axonics, Inc. | 6 | $116 |
| Boston Scientific | 4 | $109 |
| Amgen | 5 | $95 |
| Merck | 3 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $78 |
| Olympus America Inc. | 4 | $78 |
| Urogen Pharma, Inc. | 4 | $72 |
| Agiliti Surgical, Inc. | 1 | $47 |
| Myovant Sciences Inc. | 2 | $44 |
| Blue Earth Diagnostics | 2 | $38 |
| Urovant Sciences Inc | 2 | $34 |
| 180 Medical, Inc. | 1 | $26 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $26 |
| Davol Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 4 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,318 in reported general payments places this provider in the 80th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 49 | $734,113 |
| OrgovyxRelugolix | 71 | $188,780 |
| MyrbetriqMirabegron | 164 | $142,610 |
| GemtesaVibegron | 66 | $73,617 |
| Tamsulosin Hcl | 726 | $9,217 |
| Dutasteride | 178 | $5,146 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 143 | $3,208 |
| Methenamine Hippurate | 39 | $3,139 |
| Finasteride | 269 | $2,485 |
| Tadalafil | 29 | $1,640 |
| Terazosin Hcl | 12 | $1,096 |
| Desmopressin Acetate | 18 | $986 |
| Oxybutynin Chloride ErOxybutynin Chloride | 70 | $681 |
| Testosterone Cypionate | 15 | $588 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 46 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $973 | $876,724213 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $78 | $262,397137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 urology providers in Wisconsin.
Other urology in Milwaukee
- Amy GuiseMilwaukee$106K
- Mark WaplesMilwaukee$15K
- Robert OconnorMilwaukee$12K
- Matthew JohnsonMilwaukee$10K
- Peter LeonoviczMilwaukee$9K
- Arjun SivaramanMilwaukee$8K
- Graham MachenMilwaukee$7K
- Scott JohnsonMilwaukee$6K
- Luriel Smith-HarrisonMilwaukee$5K
- Pedro BandaMilwaukee$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.